Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as firstline therapy
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits. We aimed to determine the efficacy and safety of HAIC for advanced HCC as first-line therapy. Methods: A total of 54 patients who received only HAIC with 5-fluorouracil (750 mg/m2 on days 1-4) and cisplatin (25mg/m2 on days 1-4) for advanced HCC from Jan. 2009 to Dec. 2011 were selected. According to Child-Pugh class, the overall survival (OS), progression-free survival (PFS), and adverse events after HAIC were investigated retrospectively. Results: Median OS and PFS between the Child-Pugh A group (n=24) and the Child-Pugh B/C group (n=30) were 8.7(95% confidence interval [CI]: 4.7-12.7) vs. 3.7 months (95% CI: 2.0-5.3), and 7.1 (95% CI: 3.8-10.4) vs. 3.6 months (95% CI:2.0-5.2), respectively. Although median OS and PFS were not statistically significant between the two groups (P=0.079,P=0.196), the Child-Pugh class B/C tended to influence poor OS. Serious adverse events ≥ grade 3 occurred frequently in both groups (83.3 vs. 96.7%, P=0.159). Responders (22.2%, complete or partial response) significantly differed in median OS, compared to non-responders (13.1 vs. 4.4 months, P=0.019). Achievement of complete or partial response was an independent prognostic factor of OS (hazard ratio: 0.4, 95% CI: 0.2-0.8, P=0.011). Conclusions: Achievement of response after HAIC provide a survival benefit in patients with advanced HCC, but HAIC should be administered cautiously in patients with Child-Pugh class B/C, because of a relatively low survival and high incidence of serious adverse events. (Clin Mol Hepatol 2013;19:288-299)
Abstract
Background/Aims: Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits. We aimed to determine the efficacy and safety of HAIC for advanced HCC as first-line therapy. Methods: A total of 54 patients who received only HAIC with 5-fluorouracil (750 mg/m2 on days 1-4) and cisplatin (25mg/m2 on days 1-4) for advanced HCC from Jan. 2009 to Dec. 2011 were selected. According to Child-Pugh class, the overall survival (OS), progression-free survival (PFS), and adverse events after HAIC were investigated retrospectively. Results: Median OS and PFS between the Child-Pugh A group (n=24) and the Child-Pugh B/C group (n=30) were 8.7(95% confidence interval [CI]: 4.7-12.7) vs. 3.7 months (95% CI: 2.0-5.3), and 7.1 (95% CI: 3.8-10.4) vs. 3.6 months (95% CI:2.0-5.2), respectively. Although median OS and PFS were not statistically significant between the two groups (P=0.079,P=0.196), the Child-Pugh class B/C tended to influence poor OS. Serious adverse events ≥ grade 3 occurred frequently in both groups (83.3 vs. 96.7%, P=0.159). Responders (22.2%, complete or partial response) significantly differed in median OS, compared to non-responders (13.1 vs. 4.4 months, P=0.019). Achievement of complete or partial response was an independent prognostic factor of OS (hazard ratio: 0.4, 95% CI: 0.2-0.8, P=0.011). Conclusions: Achievement of response after HAIC provide a survival benefit in patients with advanced HCC, but HAIC should be administered cautiously in patients with Child-Pugh class B/C, because of a relatively low survival and high incidence of serious adverse events. (Clin Mol Hepatol 2013;19:288-299)
참고문헌 (23)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Kirikoshi H, "Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?", World J Gastroenterol, 18, pp.1933~1939 (2012)
- Bruix J, "Treatment of hepatocellular carcinoma", Hepatology, 25, pp.259~262 (1997)
- Llovet JM, "Hepatocellular carcinoma", Lancet, 362, pp.1907~1917 (2003)
- Baek YH, "Effi cacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma", World J Gastroenterol, 18, pp.3426~3434 (2012)
- Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
- Liu L, "Sorafenib blocks the RAF", MEK, PRF, pp.5, Cancer Res[DOI]
- Lee S, "Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study", Invest New Drugs, 30, pp.1150~1157 (2012)
- Jeong SW, "The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma", Asia Pac J Clin Oncol, 8, pp.164~171 (2012)
- Woo HY, "A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma", Cancer Chemother Pharmacol, 65, pp.373~382 (2010)
- Minoyama A, "Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma", J Gastroenterol, 30, pp.356~366 (1995)
- 장병국, "진행된 원발성 간세포암종에서 5-fluorouracil, cisplatin을이용한 국소적 간동맥항암제주입요법의 효과", Clinical and Molecular Hepatology, 10(2004), pp.271~278 (2004), 대한간학회
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Yamashita T, "Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma", Oncology, 81, pp.281~290 (2011)
- Ueshima K, "Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma", Oncology, 78(Suppl 1), pp.148~153 (2010)
- Katamura Y, "Intra-arterial 5-fluorouracil", interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis, 2009, pp.44, 492~502
- Yamasaki T, "Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders", Hepatol Res, 42, pp.340~348 (2012)
- Ando E, "Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases", Cancer, 95, pp.588~595 (2002)
- Obi S, "Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion", Cancer, 106, pp.1990~1997 (2006)
- Nagai H, "Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma", Cancer Chemother Pharmacol, 66, pp.1123~1129 (2010)